55
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          The EURO-ENDO registry aimed to study the management and outcomes of patients with infective endocarditis (IE).

          Methods and results

          Prospective cohort of 3116 adult patients (2470 from Europe, 646 from non-ESC countries), admitted to 156 hospitals in 40 countries between January 2016 and March 2018 with a diagnosis of IE based on ESC 2015 diagnostic criteria. Clinical, biological, microbiological, and imaging [echocardiography, computed tomography (CT) scan, 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)] data were collected. Infective endocarditis was native (NVE) in 1764 (56.6%) patients, prosthetic (PVIE) in 939 (30.1%), and device-related (CDRIE) in 308 (9.9%). Infective endocarditis was community-acquired in 2046 (65.66%) patients. Microorganisms involved were staphylococci in 1085 (44.1%) patients, oral streptococci in 304 (12.3%), enterococci in 390 (15.8%), and Streptococcus gallolyticus in 162 (6.6%). 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed in 518 (16.6%) patients and presented with cardiac uptake (major criterion) in 222 (42.9%) patients, with a better sensitivity in PVIE (66.8%) than in NVE (28.0%) and CDRIE (16.3%). Embolic events occurred in 20.6% of patients, and were significantly associated with tricuspid or pulmonary IE, presence of a vegetation and Staphylococcus aureus IE. According to ESC guidelines, cardiac surgery was indicated in 2160 (69.3%) patients, but finally performed in only 1596 (73.9%) of them. In-hospital death occurred in 532 (17.1%) patients and was more frequent in PVIE. Independent predictors of mortality were Charlson index, creatinine > 2 mg/dL, congestive heart failure, vegetation length > 10 mm, cerebral complications, abscess, and failure to undertake surgery when indicated.

          Conclusion

          Infective endocarditis is still a life-threatening disease with frequent lethal outcome despite profound changes in its clinical, microbiological, imaging, and therapeutic profiles.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion.

          This study sought to determine the value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) for diagnosing prosthetic valve endocarditis (PVE).
            • Record: found
            • Abstract: found
            • Article: not found

            Infective endocarditis in Europe: lessons from the Euro heart survey.

            To describe the characteristics, treatment, and outcomes of active infective endocarditis (IE) in Europe. Prospective survey of medical practices in Europe. 92 centres from 25 countries. The EHS (Euro heart survey) on valvar heart disease (VHD) enrolled 5001 adult patients between April and July 2001. Of those, 159 had active IE. 118 patients (74%) had native IE and 41 (26%) had prosthetic IE. Mean (SD) age was 57 (16) years. Blood cultures were obtained for 113 patients (71%) before antibiotic treatment was started. Surgery was performed in 52% of patients. Reasons for surgery were heart failure in 60%, persistent sepsis in 40%, vegetation size in 48%, or embolism in 18%. Surgery was for implantation of mechanical prosthesis in 63%, bioprosthesis in 21%, aortic homograft in 5%, and valve repair in 11%. In-hospital mortality was 12.6%, being 10.4% in the medical group and 15.6% in the surgical group. Among the total population of 5001 patients, only 50% of those with native VHD had been educated on endocarditis prophylaxis and only 33% regularly attended dental follow up. Of patients with IE who had had a procedure at risk during the preceding year only 50% had received adequate prophylaxis. The EHS on VHD shows that patients with active IE have a high risk profile and often undergo surgery. However, there are deficiencies in obtaining blood cultures and applying prophylaxis. Mortality remains high, which is a justification for the improvement of patient management through education and the implementation of guidelines.
              • Record: found
              • Abstract: found
              • Article: not found

              Improving the Diagnosis of Infective Endocarditis in Prosthetic Valves and Intracardiac Devices With 18F-Fluordeoxyglucose Positron Emission Tomography/Computed Tomography Angiography: Initial Results at an Infective Endocarditis Referral Center.

              The diagnosis of infective endocarditis (IE) in prosthetic valves and intracardiac devices is challenging because both the modified Duke criteria (DC) and echocardiography have limitations in this population. The added value of (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) and (18)F-FDG PET/CT angiography (PET/CTA) was evaluated in this complex scenario at a referral center with a multidisciplinary IE unit.

                Author and article information

                Journal
                European Heart Journal
                Oxford University Press (OUP)
                0195-668X
                1522-9645
                September 03 2019
                September 03 2019
                Affiliations
                [1 ]Cardiology Department, APHM, La Timone Hospital, Boulevard Jean Moulin, 13005 Marseille, France
                [2 ]Aix Marseille University, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France
                [3 ]Nuclear Medicine, Department of Translational Research and New Technology, Medicine University of Pisa and Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
                [4 ]Medical Imaging Center, University Medical Center Groningen, Groningen, The Netherlands
                [5 ]Bichat Hospital, APHP, DHU Fire, Paris Diderot University, Paris, France
                [6 ]University of Rennes, CHU Rennes, Inserm, LTSI – UMR 1099, Rennes, France
                [7 ]Center for Cardiovascular Diseases (CHVZ), University Hospital Brussel, Brussels, Belgium
                [8 ]EURObservational Research Programme (EORP), European Society of Cardiology, Sophia-Antipolis, France
                [9 ]Department of Cardiology, University of Medicine and Pharmacy “Carol Davila” Euroecolab, Emergency Institute of Cardiovascular Diseases “Prof. Dr C. C. Iliescu”, Bucharest, Romania
                [10 ]Department of Cardiology, Guy's and St Thomas' Hospital, London, Great Britain
                [11 ]Department of Cardiology, Hospital Quiron Barcelona
                [12 ]Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
                [13 ]Department of Cardiovascular Medicine, SOS Endocardites Unit, Henri-Mondor University Hospital, AP-HP, Creteil, France
                [14 ]Department of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania
                [15 ]Luxembourg Hospital Centre, Luxembourg
                [16 ]Cardiology Department, Gaston Bourret Hospital Centre, New Caledonia University, Noumea, New Caledonia, France
                [17 ]EURObservational Research Programme, European Society of Cardiology, France
                [18 ]ANMCO Research Center, Florence, Italy
                [19 ]Department of Cardiology, Heart Valve Clinic, University of Liege Hospital, GIGA Cardiovascular Sciences, CHU Sart Tilman, Liege, Belgium
                [20 ]Gruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy
                Article
                10.1093/eurheartj/ehz620
                31504413
                cf3971c8-24c8-4b46-a3e8-6d1c12f05286
                © 2019

                https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

                History

                Comments

                Comment on this article

                Related Documents Log